Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysisVidar Ruddox, Jan Erik Otterstad, Irene Sandven et al.|European Journal of Preventive Cardiology|2017Cited by 402
Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysisMagnus Dahl Aarvik, Jan Erik Otterstad, Irene Sandven et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2018Cited by 121
Beta-Blockers after Myocardial Infarction in Patients without Heart FailureJohn Munkhaugen, Gro Egholm, Karsten Tange Veien et al.|New England Journal of Medicine|2025Cited by 73
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyJohn Munkhaugen, Dan Atar, Hans Erik Bøtker et al.|American Heart Journal|2018Cited by 50
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristicsAnna Meta Dyrvig Kristensen, Dan Atar, Arnhild Bakken et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2023Cited by 21